secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001493152-25-009686
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Hepion shareholders approve reverse stock split (1:10-1:50) at annual meeting
-----------------------------------------------------------------------------

- All four director nominees elected (Brancaccio, Block, Lbiati, Purcell) with majority 'For' votes.
- Ratification of Grassi & Co. as auditor for FY2024 approved: 2,974,800 For, 603,560 Against.
- Advisory say-on-pay approved: 1,419,035 For, 853,863 Against, 244,418 Abstentions.
- Issuance of shares upon Series A and B Warrants approved: 1,720,659 For, 793,847 Against.
- Reverse stock split amendment approved (2,685,475 For); board to set ratio (1:10-1:50) and timing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000149315225009686/0001493152-25-009686-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000149315225009686/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-009686

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer